US authorizes first home test for three common sexually transmitted infections
The home test, developed by privately held company Visby Medical, does not require mailing samples to a lab like other existing home-based STI tests.
Keep up with the latest medical breakthroughs and healthcare trends with the Reuters Health Rounds newsletter. Sign up here.
The new test for common STIs chlamydia, gonorrhea, and trichomoniasis, which is intended for females with or without symptoms, delivers results in about 30 minutes.
All three infections can be treated with antibiotics, but if left untreated, can cause serious health complications for patients, including infertility, the FDA said.
Visby's single-use test includes a collection kit and a powered testing device, which communicates securely with the Visby Medical App to display results when the test is complete.
"Expanding access to tests for STIs is an important step toward earlier and increased diagnosis, which can result in increased treatment and reduced spread of infection," said Courtney Lias, director of the Office of In Vitro Diagnostic Devices in the FDA's Center for Devices and Radiological Health.
The common STIs caused by different pathogens have distinct symptoms such as painful urination, lower abdominal pain, heavy menstrual bleeding, and itching or irritation in the genital area.
More than 2.2 million cases of chlamydia and gonorrhea were diagnosed and reported in the U.S. in 2023, according to a report, opens new tab on STIs from the Centers for Disease Control and Prevention (CDC).
It is estimated that trichomoniasis is the most prevalent non-viral STI worldwide, affecting about 2.6 million people in the U.S., according to the CDC.
Last year, the FDA authorized the first at-home, over-the-counter test to detect syphilis antibodies in human blood.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Independent
an hour ago
- The Independent
Family issues warning as son dies after taking highly addictive over-the-counter supplement: ‘The government doesn't step in'
A family in Washington is warning about the dangers of kratom — a supplement that can be bought in some gas stations — after they say their son died from using the substance. On the day Jordan McKibban, 37, died in 2022, he reportedly mixed kratom with his lemonade, according to his mother, Pam Mauldin, who spoke to the New York Post. Kratom is marketed as an "all-natural" supplement that can help reduce pain, anxiety, and depression, among other ailments. For some individuals who are wary of typical pharmaceutical medicines — as McKibban reportedly was — kratom can be an attractive alternative. Mauldin found her son unconscious in his room after he drank the kratom-lemonade mixture. She attempted CPR, but could not revive him. 'I've lost my son. I've lost my grandchildren that I could have had, I've lost watching him walk down that aisle, watching him have a life that I get to watch with my other kids. I've lost enjoying these years with him,' she told the New York Post. After his death, an autopsy found that McKibban death was caused by mitragynine, which is found in ktraom. Kratom is made from a Southeast Asian plant and can act as a stimulant when taken in lower doses and a sedative when taken at higher doses. The substance can be bought from online retailers and in stores legally. The U.S. Food and Drug Administration notes that kratom hasn't been shown to be safe or effective at treating any medical conditions. The agency has described it as a "drug of concern." Despite its open availability, national poison control centers have documented 1,807 calls about kratom exposure between 2011 and 2017, and the calls are becoming more frequent, according to Dr Michael Greco, who spoke to the New York Post. He warned that kratom use can, in some people, cause them to experience agitation and "sometimes even psychosis." However, kratom deaths are rare. In McKibban's situation, he was told that he could not overdose on the substance, and that he would simply vomit if he took too much, according to his mother. She noted that her son's kratom bags had no instructions on them or dosage suggestions. 'There have been hundreds of people killed from this, and they don't pull it. The government doesn't step in,' she said. That may be changing. U.S. Secretary of Health and Human Services Robert F Kennedy Jr announced in late July that he plans to crack down on kratom. 'I became an addict because [heroin] was so available, but I had to go to the South Bronx or the Lower East Side. But now you can go to any gas station,' Kennedy told reporters on July 29 while discussing the substance. 'They're marketing them to children: They're gummy bears, they're bright colors, they're candy-flavored. This is really a sinister, sinister industry.' He was referring to a reportedly more addictive and possibly more dangerous offshoot of kratom called 7-hydroxymitragynine. Dr Robert Levy, an addiction and family doctor, told the New York Post that the substance can have similar effects to opioids. 'There's always been concern around kratom because if you take enough of it, kratom does act like an opioid, and people can become addicted to it and have withdrawal from it and overdose on it and ruin their lives on it, like anybody else that has a substance use disorder,' Levy said. He said the offshoot product that is "much more addicting and much more problematic" has infiltrated the market, and many consumers don't know the difference. The FDA recently recommended 7-hydroxymitragynine be classified as an illicit substance. '7-OH is an opioid that can be more potent than morphine,' FDA Commissioner Marty Makary, said in a press release. 'We need regulation and public education to prevent another wave of the opioid epidemic.' Levy recommended that parents talk to their children or loved ones about the substance and remind them that just because something is "all-natural" and plant-derived does not mean it's safe for consumption. "Arsenic is also from a plant," he noted. He advised that anyone with a family member struggling with substance abuse of any kind to seek out available resources and treatment options.
The Independent
3 hours ago
- The Independent
FDA flags problems with two Boston Scientific heart devices tied to injuries and deaths
U.S. health regulators are warning doctors and patients about safety issues with two separate Boston Scientific heart devices recently linked to injuries and deaths. The Food and Drug Administration issued two alerts Wednesday about electrical problems tied to the company's heart-zapping defibrillator systems and a separate issue with a heart implant used to reduce stroke risk. The agency said the company's Endotak Reliance defibrillator wires can become calcified, leading to failures in delivering life-saving shocks to the heart, according to the FDA. Defibrillators are surgically placed in the upper chest, where they monitor irregular heartbeats and use electrical shocks to jolt the heart back to normal. As of July 24, Boston Scientific has reported 386 serious injuries and 16 deaths associated with this issue, the agency said. Ten of the deaths were judged to be due to the device failing to function properly, the company said in an email. Four were linked to attempts to surgically remove the devices from patients and two others were deemed unrelated to the implants. Boston Scientific's wires were distributed between 2002 and 2021 and are no longer available, the company noted in its letter to doctors. Some patients will need to have the devices replaced, though physicians should weigh the risks of the removal procedure. In a separate notice, the FDA said Boston Scientific recently updated instructions for implanting its Watchman device, which closes a portion of the heart's left atrium to reduce the risk of stroke. In a letter to physicians, the company noted that there is an increased risk of blockages in the bloodstream depending on the level of anesthesia for patients undergoing the initial implantation procedure. Watchman is an alternative to long-term treatment with blood thinners for patients at increased risk of stroke. As of July 30, the company has reported 120 serious injuries and 17 deaths related to the issue, the FDA said. A company investigation concluded that the safety issue 'is not associated with the design or manufacture of any component of the Watchman system. Heart devices, including defibrillators and other implants, are Boston Scientific's largest business, making up two-thirds of its $5 billion in revenue for the most recent quarter. Shares of Boston Scientific Corp. fell nearly 1.8 percent Wednesday to close at $102.95 in trading. ___ The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute's Department of Science Education and the Robert Wood Johnson Foundation. The AP is solely responsible for all content.
Reuters
4 hours ago
- Reuters
US FDA approves Jazz Pharma's drug for rare brain tumor
Aug 6 (Reuters) - The U.S. Food and Drug Administration said on Wednesday that it has approved Jazz Pharmaceuticals' (JAZZ.O), opens new tab drug to treat diffuse midline glioma, a rare and aggressive tumor, in adults and children aged one year and older. This marks the first FDA approval of a systemic therapy for diffuse midline glioma with a specific mutation that has progressed after previous treatments, the agency said. Diffuse midline glioma (DMG) is a rare and aggressive brain tumor that primarily affects children and young adults. It develops in the brain's and spinal cord's midline structures, such as the brainstem, thalamus, and spinal cord. Jazz Pharmaceuticals acquired the drug in March through its $935 million purchase of Chimerix.
